New therapeutics strategies in renal cell carcinoma

被引：1

作者：

Meric, J. -B. ^{[1
]}

Billemont, B. ^{[2
]}

Rixe, O. ^{[3
]}

机构：

[1] Ctr Med Bligny, Dept Oncohematol, F-91640 Briis Sous Forges, France

[2] Hop Cochin, AP HP, Ctr Etud & Recours Inhibiteurs Angiogenese, F-75014 Paris, France

[3] Univ Cincinnati, Barrett Canc Ctr, Cincinnati, OH USA

来源：

BULLETIN DU CANCER | 2010年 / 97卷

关键词：

renal cell carcinoma; angiogenesis; targeted therapy; VEGF; immunotherapy; axitinib; HEDGEHOG SIGNALING PATHWAY; TIE2-EXPRESSING MONOCYTES; TUMOR ANGIOGENESIS; CANCER; NEUROPILIN-1; HYPOXIA; GROWTH; ACTIVATION; INHIBITORS; GENETICS;

D O I：

10.1684/bdc.2010.1070

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

New medical strategies have emerged over the past decade for the treatment of advanced renal cell carcinoma based on the discovery of specific molecular abnormalities. However, molecular targeted therapeutics including anti-angiogenics have demonstrated significant limits ( limited impact on overall survival, development of potential severe toxicities). We review the future directions for drug development based on specific interaction with cellular and extra-cellular pathways. Both von Hippel-Lindau alterations and high immunogenicity profile represent two remarkable characteristics identified in clear cell carcinoma. The new generation of anti-angiogenics ( including HIF, Notch, or angiopoietin inhibitors) and recent developments in immunotherapy also provide opportunities to modify the prognosis of advanced renal cell carcinoma.

引用

页码：S53 / S63

页数：11

共 50 条

[21] Mechanisms of sunitinib resistance in renal cell carcinoma and associated opportunities for therapeutics
Wang, Yunxia
Liu, Xiaolin
Gong, Luyao
Ding, Weihong
Hao, Wenjing
Peng, Yeheng
Zhang, Jun
Cai, Weimin
Gao, Yuan
BRITISH JOURNAL OF PHARMACOLOGY, 2023, 180 (23) : 2937 - 2955
[22] Immune Checkpoint Inhibitors as Novel Targets for Renal Cell Carcinoma Therapeutics
Bailey, Alexandra
McDermott, David F.
CANCER JOURNAL, 2013, 19 (04): : 348 - 352
[23] Novel metabolic signatures in renal cell carcinoma for precision diagnostics and therapeutics
Amaro, F.
Carvalho, M.
Carvalho-Maia, C.
Jeronimo, C.
Henrique, R.
Bastos, M. D. L.
Guedes de Pinho, P.
Pinto, J.
TOXICOLOGY LETTERS, 2024, 399 : S251 - S251
[24] The Current Role of Immunotherapy for Renal Cell Carcinoma in the Era of Targeted Therapeutics
Wong, Michael K. K.
CURRENT ONCOLOGY REPORTS, 2008, 10 (03) : 259 - 263
[25] Use of Circular RNAs in Diagnosis, Prognosis and Therapeutics of Renal Cell Carcinoma
Osca-Verdegal, Rebeca
Beltran-Garcia, Jesus
Luis Gorriz, Jose
Martinez Jabaloyas, Jose Maria
Pallardo, Federico, V
Luis Garcia-Gimenez, Jose
FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2022, 10
[26] Editorial: current strategies in advanced renal cell carcinoma
Haddad, Ahmed Q.
Margulis, Vitaly
Schmidinger, Manuela
CURRENT OPINION IN UROLOGY, 2015, 25 (05) : 357 - 357
[27] Targeted therapeutic strategies for the management of renal cell carcinoma
Singer, Eric A.
Gupta, Gopal N.
Srinivasan, Ramaprasad
CURRENT OPINION IN ONCOLOGY, 2012, 24 (03) : 284 - 290
[28] Current immuno therapeutic strategies in renal cell carcinoma
Amato, Robert J.
SURGICAL ONCOLOGY CLINICS OF NORTH AMERICA, 2007, 16 (04) : 975 - +
[29] Strategies for favorable group of metastasis renal cell carcinoma
Oki, Ryosuke
ANNALS OF ONCOLOGY, 2023, 34 : S1362 - S1362
[30] CURRENT STRATEGIES FOR IMMUNOTHERAPY OF RENAL-CELL CARCINOMA
HEICAPPELL, R
ACKERMANN, R
WORLD JOURNAL OF UROLOGY, 1991, 9 (04) : 204 - 209

← 1 2 3 4 5 →